Bersanlimab
Modify Date: 2024-02-06 10:04:36
Bersanlimab structure
|
Common Name | Bersanlimab | ||
|---|---|---|---|---|
| CAS Number | 1987854-08-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BersanlimabBersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects[1]. |
| Name | Bersanlimab |
|---|
| Description | Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects[1]. |
|---|---|
| Related Catalog | |
| In Vitro | BI-505（1 ng/mL-1000 μg/mL）剂量依赖性地诱导表达 ICAM-1 的 Ramos、Raji 和 Daudi 淋巴瘤细胞的程序性细胞死亡 (PCD)[1]。 |
| In Vivo | Bersanlimab（BI-505；20 mg/kg；腹腔注射；每周两次；持续 21 天）显着减少肿瘤生长并延长动物存活期[1]。 Animal Model: SCID mice injected with ARH-77 cells[1] Dosage: 20 mg/kg Administration: i.p.; twice-weekly; for 21 days Result: Significantly reduced tumor growth and prolonged animal survival. |
| References |
| No Any Chemical & Physical Properties |